Newsbot

DE plans to scale its mixed-fleet strategy with the Tenna acquisition, expanding customer-focused construction technology offerings.

Nvidia shares breakout again as analysts upgrade the outlook on the worlds leading AI stock

CGAU, CMC and SYIEY stand out as PEG-driven value plays for 2026 as higher rates and shifting returns fuel a rotation away from growth.

C ramps up Japan investment banking, planning a 30% headcount boost by 2026 as a record M&A boom reshapes the corporate landscape.

Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.

Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Lets dive in.

With WFC at a 52-week high, does improving U.S. economic confidence and expectations for 2026 support further upside? Let us find out.

HBRIYs $3.2B deal to buy LLOG delivers oil-weighted deepwater assets and secures a long-sought entry into the Gulf of America.

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

ALLY hits a 52-week high after stronger U.S. GDP. However, asset quality, NIM pressure and expenses keep the stock a cautious hold.

Invest in Gabelli mutual funds such as GAGCX, GABCX and GICPX for a research-driven portfolio.